660 related articles for article (PubMed ID: 33167705)
1. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
[TBL] [Abstract][Full Text] [Related]
2. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
[TBL] [Abstract][Full Text] [Related]
3. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
[TBL] [Abstract][Full Text] [Related]
4. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
[TBL] [Abstract][Full Text] [Related]
5. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
Kornowski R; Konigstein M; Jonas M; Assali A; Vaknin-Assa H; Segev A; Danenberg H; Halabi M; Roguin A; Kerner A; Lev E; Karamasis GV; Johnson TW; Anderson R; Blaxill J; Jadhav S; Hoole S; Witberg G; Issever MO; Ben-Yehuda O; Baumbach A
J Am Heart Assoc; 2024 Jan; 13(2):e029051. PubMed ID: 38214256
[TBL] [Abstract][Full Text] [Related]
7. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
[TBL] [Abstract][Full Text] [Related]
8. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
9. Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial.
Lee SY; Kim JS; Yoon HJ; Hur SH; Lee SG; Kim JW; Hong YJ; Kim KS; Choi SY; Shin DH; Nam CM; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
JACC Cardiovasc Imaging; 2018 Dec; 11(12):1810-1819. PubMed ID: 29454763
[TBL] [Abstract][Full Text] [Related]
10. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
[TBL] [Abstract][Full Text] [Related]
11. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents.
Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Colombo A; Gilard M; Palmerini T; Stone GW
Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27803041
[TBL] [Abstract][Full Text] [Related]
12. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
[TBL] [Abstract][Full Text] [Related]
13. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
[TBL] [Abstract][Full Text] [Related]
14. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
Yeh RW; Silber S; Chen L; Chen S; Hiremath S; Neumann FJ; Qiao S; Saito S; Xu B; Yang Y; Mauri L
JACC Cardiovasc Interv; 2017 Feb; 10(3):247-254. PubMed ID: 28109872
[TBL] [Abstract][Full Text] [Related]
15. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
[TBL] [Abstract][Full Text] [Related]
16. Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE.
Windecker S; Latib A; Kedhi E; Kirtane AJ; Kandzari DE; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Hudec M; Poliacikova P; Kahar Bin Abdul Ghapar A; Selvaraj K; Petrov I; Mylotte D; Pinar E; Moreno R; Fabbiocchi F; Pasupati S; Kim HS; Aminian A; Tie C; Wlodarczak A; Hur SH; Marx SO; Ali ZA; Parke M; Lung TH; Stone GW;
JACC Cardiovasc Interv; 2022 Jun; 15(11):1153-1163. PubMed ID: 35680195
[TBL] [Abstract][Full Text] [Related]
17. Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial.
Postma W; Fabris E; Van der Ent M; Hermanides R; Buszman P; Von Birgelen C C; Cook S; Wedel H; De Luca G; Delewi R; Zijlstra F; Kedhi E
Catheter Cardiovasc Interv; 2020 Mar; 95(4):706-710. PubMed ID: 31268629
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
[TBL] [Abstract][Full Text] [Related]
19. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Yun KH; Lee SY; Cho BR; Jang WJ; Song YB; Oh JH; Chun WJ; Park YH; Im ES; Jeong JO; Oh SK; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY;
J Am Heart Assoc; 2021 Jan; 10(1):e018366. PubMed ID: 33345567
[TBL] [Abstract][Full Text] [Related]
20. Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy.
Landi A; Wlodarczak A; Tölg R; Kelbæk H; Legutko J; Galli S; Godin M; Toth GG; Lhermusier T; Honton B; Dietrich PL; Stammen F; Ferdinande B; Silvain J; Capodanno D; Cayla G; Valgimigli M;
J Cardiovasc Transl Res; 2023 Oct; 16(5):1135-1143. PubMed ID: 37264295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
